They emphasized that we should pay more attention to whether Impassion130 is a false positive or not, they are more concerned about the signal of harm seen in Impassion131, Similarly, advocacy organizations for patients with breast cancer also came to the conclusion “the only results that we have in the setting of breast cancer from appropriately powered analyses show no overall survival benefit with atezolizumab, or a negative trend in OS, and either no or a 2.6-month benefit of PFS in patients with TNBC, regardless of their PD-L1 expression” (61). Here, CD274 is linked to breast carcinoma.